ADARx Pharmaceuticals, Inc.: Li Zhen discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Li Zhen disclosed a stake exceeding 5% in ADARx Pharmaceuticals, Inc. via a Schedule 13G filing with the SEC (accession 0001729510-26-000009). The filing signals that the investor has crossed the threshold requiring public disclosure of a passive position in the company. The exact share count and percentage were not specified in the headline disclosure. Investors will watch for further 13G amendments or 13D filings to gauge whether the stake remains passive or becomes activist.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Li Zhen, ADARx Pharmaceuticals, Inc.